Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cardfail.2025.05.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS-HF trial.
Eur J Heart Fail
September 2025
Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Aims: The estimated glucose disposal rate (eGDR) is a simple, non-invasive measure of insulin resistance. In this exploratory analysis of FINEARTS-HF, we evaluated whether lower eGDR, reflecting greater insulin resistance, is associated with adverse outcomes in heart failure (HF).
Methods And Results: The eGDR was calculated at baseline using waist circumference, glycated haemoglobin, and hypertension status.
A primary care guide to the screening and pharmacologic management of chronic kidney disease in people living with type 2 diabetes.
Prim Care Diabetes
October 2025
University of British Columbia, Vancouver, Canada.
This paper reports the expert opinions and recommendations made by primary care physicians (PCPs) to optimize screening and management of chronic kidney disease (CKD) associated with diabetes and presents algorithms to provide a practical and simplified guide for PCPs. Individuals living with type 2 diabetes (T2D) should be screened early and at regular intervals for CKD using both estimated glomerular filtration rate and urinary albumin-to-creatinine ratio testing. The risk of CKD assessed using the Kidney Disease: Improving Global Outcomes heatmap should be reviewed at least annually to optimize treatment to slow progression of CKD.
View Article and Find Full Text PDFAnthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of Three Global Trials.
J Am Coll Cardiol
August 2025
Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Electronic address:
Background: Obesity is a core pathophysiological contributor to cardiovascular, kidney, and metabolic (CKM) conditions. However, the association between different adiposity-related anthropometrics and cardiovascular outcomes in persons with CKM conditions has not been rigorously explored.
Objectives: To examine cardiovascular outcomes and treatment effects of finerenone according to different adiposity-related anthropometrics.
Mineralocorticoid receptor regulates vascular damage by inducing autophagy in mice with obesity and hypertension.
Nutr Metab Cardiovasc Dis
June 2025
Department of Cardiology, The Sixth Medical Center of Chinese People's Liberation Army General Hospital, No.6 Fucheng Road, Beijing, 100048, China; The School of Medicine, Nankai University, No.94 Weijin Road, Nankai District, Tianjin, 300071, China; Department of Cardiology, Chinese People's Libera
Background And Aim: This study aimed to explore the effect and potential mechanism of mineralocorticoid receptor (MR) in vascular impairment in mice with metabolic disorders(obesity and hypertension).
Methods And Results: C57BL/6 mice were used in this study. D12492 were used to fed the mice for obesity for more than 4 months and AngII was used to induce hypertension.